A World Leader in Bacterial Nanocellulose Biopolymers
About Axcelon Biopolymers
Axcelon Biopolymers Corporation is an innovative biomaterials company focused on leveraging its unique Bacterial NanoCellulose (BNC) platform technology to develop bacterial cellulose-based, high value products for wound care, medical devices, and industrial applications.
Axcelon is unique among early stage medical device companies. The Company is positioned to generate attractive near-term revenues from a licensed ready-to-market product and has impressive mid and long-term prospects for developing innovative and proprietary materials from its platform technology. This healthy combination will enable Axcelon to leverage the revenues and experience gained in the near-term to fully exploit the Company’s significant long-term prospects..
Three Key Business Areas
The Company operates in three key business areas:1. Axcelon Dermacare Inc. - Commercial wound care division now selling Nanoderm™, a high clinical impact and cost effective wound care product, with a follow-on product launch (Nanoderm™Ag) in 2017
2. Axcelon Biomedical – R&D division developing a strong biomaterial-based medical device pipeline with significant licensing and revenue potential
3. Axcelon Biomaterials – R&D division developing a novel, disruptive technology in bacterial cellulose production for non-medical and industrial applications
Axcelon’s Business Model & Strategy
Axcelon is focused on becoming a world leader in the development and manufacturing of novel and cost-efficient bacterial cellulose-based products for the biomedical device industry and for non-medical industrial applications.
Our business model involves developing bacterial cellulose-based biomaterials and products to a stage where they can be licensed to commercial partners for specific therapeutic areas. Axcelon is also looking for co-development partnership opportunities to accelerate its development pipeline.